Search results
Jan 11, 2021 · ClearMind Biomedical announced today that it received FDA clearance for its Axonpen novel neuroendoscope system.. Los Angeles-based ClearMind Biomedical’s Axonpen system is designed for the ...
Nov 17, 2022 · VANCOUVER, Nov. 17, 2022 -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the closing of its underwritten public offering of 1,153,847 common shares at a price to the public of US$6.50 ...
Jan 12, 2021 · Requires only a narrow channel of 6.5mm through the skull for insertion into the brain.
Nov 23, 2022 · VANCOUVER, November 23, 2022 -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the initiation of clinical batches of production of its novel psychedelic-derived drug candidate, the MEAI ...
Date Received: 05/15/2020: Decision Date: 11/27/2020: Decision: Substantially Equivalent (SESE) Regulation Medical Specialty: Neurology
Aug 1, 2022 · Clearmind Biomedical is funded by Darwin Venture Management. Funding Rounds. Edit Funding Rounds Section. Number of Funding Rounds 1. Clearmind Biomedical has raised ...
Clearmind Medicine Inc. 101 – 1220 W 6 Ave Vancouver, BC V6H1A5 Investor Relations: US: CMND@crescendo-ir.com invest@clearmindmedicine.com Telephone: (604) 260 1566 Sitemap
